Functional analysis of the molecules modulating the proliferative signals of human myeloma cells by IL-6
Functional analysis of the molecules modulating the proliferative signals of human myeloma cells by IL-6
批准号:
12670991
负责人:
ISHIKAWA Hideaki
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Interleukin-6 (IL-6) has a variety of biological functions in different cells and is a growth factor for human myeloma cells. IL-6 receptor complexes consist of the IL-6 receptor a chain (IL-6Rα) and gp130, the latter being commonly used as a signal-transducing molecule by the members of the IL-6 family of cytokines. Specific intracellular signals mediated by IL-6 receptor complexes, such as signal transducers and activators of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) 1/2, are considered to be responsible for inducing a variety of cellular responses. CD45 antigens are initially characterized as leukocyte common antigen expressed on all hematopoietic cells except for mature erythrocytes and platelets. Dephosphorylation of the COOH-terminal tyrosine residue of src family kinases by CD45 phosphatase has been implicated a mechanism of src family kinase activation. The activated src family kinases mediate downstream the signals of several extracellular stimuli … More , such as growth factors, cytokines, and antigen stimulation, leading to diversification and amplification of the initial signals. Although the roles of CD45 have been extensively studied for antigen receptors in B and T cells, its physiological consequences in other hematopoietic cells remain largely unknown. We recently found that myeloma cells expressing CD45 form a proliferating population in multiple myeloma (MM). Thus, MM seems a good example in which to address the biological functions of CD45 molecules in cell proliferation promoted by the cytokine, IL-6. In MM, IL-6 only enhanced the proliferation of CD45^+ tumor cells that harbored the IL-6-independent activation of src family kinases even though STAT3 and ERK1/2 could be activated in response to IL-6 in both CD45^+ and CD45^- cells. Furthermore, the IL-6-induced proliferation of CD45^+ U266 myeloma cells was significantly suppressed by Lyn-specific antisense oligodeoxynucleotides or a selective src kinase inhibitor. These results indicates that the activation of both STATS and ERK1/2 is not sufficient for IL-6-induced proliferation of myeloma cell lines that require src family kinase activation independent of IL-6 stimulation. Thus, the activation of the src family kinases associated with CD45 expression is a prerequisite for the proliferation of myeloma cell lines by IL-6. We propose a mechanism for IL-6-induced cell proliferation that is strictly dependent upon the cellular context in myeloma.This is also supported by another finding that KMS11 expressing fibroblast growth factor receptor (FGFR) 3 proliferated in response to IL-6 together with FGF. IL-6 or FGF alone failed to enhance the proliferation of KMS11 myeloma cell line. FGF could activated several signaling molecules different from those by IL-6, and both together finally induce the proliferative signals in KMS11 that does not express CD45. Less
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Ishikawa, H.: "CD19 expression and growth inhibition of tumors in human multiple myeloma"Leuk. Lymphoma. (in press). (2002)
Ishikawa, H.:“人多发性骨髓瘤中 CD19 的表达和肿瘤生长抑制”Leuk。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ishikawa, H.: "CD19 expression and growth inhibition of tumors in human multiple myeloma."Leuk. Lymphoma. (in press). (2002)
Ishikawa, H.:“人类多发性骨髓瘤中的 CD19 表达和肿瘤生长抑制。”Leuk。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ishikawa,H.: "Pax-5 genes and CD19 molecules in human myeloma"Jpn. J. Clin. Hematol. 41 (5). 404-407 (2000)
Ishikawa,H.:“人类骨髓瘤中的 Pax-5 基因和 CD19 分子”Jpn。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ishikawa,H.: "Pax-5 and plasmacytoid lymphoma"Hematol, Frontier. 10 (9). 1185-1192 (2000)
Ishikawa,H.:“Pax-5 和浆细胞样淋巴瘤”Hematol,Frontier。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ishikawa,H.: "Growth mechanisms of myeloma cells -mechanism of proliferation by interleukin-6"Hematol, Frontier. 12 (5) (in press). (2002)
Ishikawa,H.:“骨髓瘤细胞的生长机制 - 白细胞介素 6 的增殖机制”Hematol,Frontier。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 20 条
Development and the utilization of the social science education unification program to promote new combination of the knowledge
-
批准号:24650534
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$1.33万
-
财政年份:2012
-
负责人:ISHIKAWA Hideaki
-
依托单位:
The Role of the Lyn-PI 3-kinase signaling pathways and PKM2 in the myeloma cell proliferation
-
批准号:22591039
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2010
-
负责人:ISHIKAWA Hideaki
-
依托单位:
The origin of analytic properties of zeta functions on the domain where they are divergent
-
批准号:22740019
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$1.25万
-
财政年份:2010
-
负责人:ISHIKAWA Hideaki
-
依托单位:
Analysis of the CD45-Lyn-mediated signaling pathways in theIL-6-induced myeloma cell proliferation
-
批准号:19591115
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2007
-
负责人:ISHIKAWA Hideaki
-
依托单位:
Analysis of the IL-6-mediated intracellular signaling molecules in myeloma cell growth
-
批准号:17590999
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2005
-
负责人:ISHIKAWA Hideaki
-
依托单位:
Meaning of Conversation in an Age of Social Change. - through Yang Du
-
批准号:11610018
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.6万
-
财政年份:1999
-
负责人:ISHIKAWA Hideaki
-
依托单位:
Involvement of CD19 molecules in proliferation of human immature myeloma cells by interleukin-6
-
批准号:10670952
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:1998
-
负责人:ISHIKAWA Hideaki
-
依托单位:
国内基金
海外基金
登录
查看更多内容
早期滋养型肠内营养联合益生菌对重症卒中患者喂养耐受性及TNF-α/IL-6水平的影响研究
-
批准号:2026JJ81631
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:廖思思
-
依托单位:
七氟烷通过调控IL-6/FSP1轴抑制心肌铁死亡减轻心肌缺血再灌注损伤的机制研究
-
批准号:JCZRLH202601296
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
盐酸小檗碱抑制NF-κB/IL-6/STAT3信号通路重塑免疫微环境并增敏肺癌免疫治疗的研究
-
批准号:JCZRLH202600985
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
双歧杆菌与消退素RvD1协同调控IL-6/STAT3/Notch信号轴介导结肠癌EMT及免疫调节的机制研究
-
批准号:JCZRLH202601410
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于"热证可灸"理论的中药联合铺棉灸治疗带状疱疹急性期的临床疗效及对血清SP、β-EP、IL-6、IL-10、NSE水平的影响
-
批准号:2026JJ81075
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:黄迎春
-
依托单位:
早产儿脑白质损伤的 MRI 影像学特征联合炎症因子组合(IL-6、TNF-α、IL-1β)与神经系统损害关联研究
-
批准号:JCZRLH202601761
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于IL-6/STAT3通路巨噬细胞极化调控免疫反应在胸膜结核瘤形成中的机制
-
批准号:2026JJ82516
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张锋
-
依托单位:
基于“截断扭转”学说探讨凉膈散通过IL-6/STAT3/RORγt轴调控脓毒症Th17/Treg稳态的机制及临床研究
-
批准号:2026JJ82600
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:黄磊
-
依托单位:
从肝失疏泄探讨肝脏代谢物介导IL-6/STAT3通路调控GABA能系统对睡眠节律影响的机制及逍遥散的干预作用
-
批准号:2026JJ30175
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:滕永杰
-
依托单位:
炎症因子组合(IL-6、TNF-α、IL-1β)动态监测在极低出生体重儿坏死性小肠结肠炎早期预测中的价值研究
-
批准号:JCZRLH202601488
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: